Advertisement


Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Amit Sanyal, MD: A Clinician’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Advertisement